Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts
Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blockers, had reduced breast cancer-specific or all-cause mortality...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research : BCR 2016-12, Vol.18 (1), p.119-119, Article 119 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119 |
|---|---|
| container_issue | 1 |
| container_start_page | 119 |
| container_title | Breast cancer research : BCR |
| container_volume | 18 |
| creator | Cardwell, Chris R Pottegård, Anton Vaes, Evelien Garmo, Hans Murray, Liam J Brown, Chris Vissers, Pauline A J O'Rorke, Michael Visvanathan, Kala Cronin-Fenton, Deirdre De Schutter, Harlinde Lambe, Mats Powe, Des G van Herk-Sukel, Myrthe P P Gavin, Anna Friis, Søren Sharp, Linda Bennett, Kathleen |
| description | Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blockers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts.
Incident breast cancer patients were identified from eight cancer registries and compiled through the European Cancer Pharmacoepidemiology Network. Propranolol and non-selective beta-blocker use was ascertained for each patient. Breast cancer-specific and all-cause mortality were available for five and eight cohorts, respectively. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CIs) for cancer-specific and all-cause mortality by propranolol and non-selective beta-blocker use. HRs were pooled across cohorts using meta-analysis techniques. Dose-response analyses by number of prescriptions were also performed. Analyses were repeated investigating propranolol use before cancer diagnosis.
The combined study population included 55,252 and 133,251 breast cancer patients in the analysis of breast cancer-specific and all-cause mortality respectively. Overall, there was no association between propranolol use after diagnosis of breast cancer and breast cancer-specific or all-cause mortality (fully adjusted HR = 0.94, 95% CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively). There was little evidence of a dose-response relationship. There was also no association between propranolol use before breast cancer diagnosis and breast cancer-specific or all-cause mortality (fully adjusted HR = 1.03, 95% CI, 0.86, 1.22 and HR = 1.02, 95% CI, 0.94, 1.10, respectively). Similar null associations were observed for non-selective beta-blockers.
In this large pooled analysis of breast cancer patients, use of propranolol or non-selective beta-blockers was not associated with improved survival. |
| doi_str_mv | 10.1186/s13058-016-0782-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_500695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A472527900</galeid><sourcerecordid>A472527900</sourcerecordid><originalsourceid>FETCH-LOGICAL-c598t-253d217d1e8ed376bff2ae2f00965aac12744721448ecd6887d10af21168cb913</originalsourceid><addsrcrecordid>eNptkk1vFSEUhonR2Fr9AW4MiRs3U4Hha1yYNE39SJroQhN3yGUOLZUZrjBzTf-9TOZae41hATnnOS-cw4vQc0pOKdXydaEtEbohVDZEadaIB-iYcikawdm3h_fOR-hJKTeEUKWFfoyOmOqIJFwdo--fc9pmO6aYIrZjj8ucd2FnI_Y5DXiTwZYJOzs6yG-wxduUIvSVtPG2hIKTxxdzlQA7HsLYpeuUp_IUPfI2Fni230_Q13cXX84_NJef3n88P7tsnOj01DDR9oyqnoKGvlVy4z2zwDwhnRTWOsoU54pRzjW4XmpdUWI9o1Rqt-loe4KaVbf8gu28MdscBptvTbLB7EM_6gmMIER2ovJvV75mBugdjFO28aDsMDOGa3OVdkbQtr5PVoFXe4Gcfs5QJjOE4iBGO0Kai6GaCyZEK0lFX_6D3qQ51xGuFG9VbeMvdWUjmDD6VO91i6g5q62L5dMWrdP_UHX1MASXRvChxg8K6Frgciolg7_rkRKz2MisNjLVRmaxkVmG8-L-cO4q_vim_Q1e9sMX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1845437116</pqid></control><display><type>article</type><title>Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SWEPUB Freely available online</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Cardwell, Chris R ; Pottegård, Anton ; Vaes, Evelien ; Garmo, Hans ; Murray, Liam J ; Brown, Chris ; Vissers, Pauline A J ; O'Rorke, Michael ; Visvanathan, Kala ; Cronin-Fenton, Deirdre ; De Schutter, Harlinde ; Lambe, Mats ; Powe, Des G ; van Herk-Sukel, Myrthe P P ; Gavin, Anna ; Friis, Søren ; Sharp, Linda ; Bennett, Kathleen</creator><creatorcontrib>Cardwell, Chris R ; Pottegård, Anton ; Vaes, Evelien ; Garmo, Hans ; Murray, Liam J ; Brown, Chris ; Vissers, Pauline A J ; O'Rorke, Michael ; Visvanathan, Kala ; Cronin-Fenton, Deirdre ; De Schutter, Harlinde ; Lambe, Mats ; Powe, Des G ; van Herk-Sukel, Myrthe P P ; Gavin, Anna ; Friis, Søren ; Sharp, Linda ; Bennett, Kathleen</creatorcontrib><description>Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blockers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts.
Incident breast cancer patients were identified from eight cancer registries and compiled through the European Cancer Pharmacoepidemiology Network. Propranolol and non-selective beta-blocker use was ascertained for each patient. Breast cancer-specific and all-cause mortality were available for five and eight cohorts, respectively. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CIs) for cancer-specific and all-cause mortality by propranolol and non-selective beta-blocker use. HRs were pooled across cohorts using meta-analysis techniques. Dose-response analyses by number of prescriptions were also performed. Analyses were repeated investigating propranolol use before cancer diagnosis.
The combined study population included 55,252 and 133,251 breast cancer patients in the analysis of breast cancer-specific and all-cause mortality respectively. Overall, there was no association between propranolol use after diagnosis of breast cancer and breast cancer-specific or all-cause mortality (fully adjusted HR = 0.94, 95% CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively). There was little evidence of a dose-response relationship. There was also no association between propranolol use before breast cancer diagnosis and breast cancer-specific or all-cause mortality (fully adjusted HR = 1.03, 95% CI, 0.86, 1.22 and HR = 1.02, 95% CI, 0.94, 1.10, respectively). Similar null associations were observed for non-selective beta-blockers.
In this large pooled analysis of breast cancer patients, use of propranolol or non-selective beta-blockers was not associated with improved survival.</description><identifier>ISSN: 1465-542X</identifier><identifier>ISSN: 1465-5411</identifier><identifier>EISSN: 1465-542X</identifier><identifier>DOI: 10.1186/s13058-016-0782-5</identifier><identifier>PMID: 27906047</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Angiogenesis Inhibitors - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Care and treatment ; Cohort Studies ; Development and progression ; Europe ; Female ; Health aspects ; Humans ; Proportional Hazards Models ; Propranolol - therapeutic use ; Propranolol hydrochloride ; Treatment Outcome</subject><ispartof>Breast cancer research : BCR, 2016-12, Vol.18 (1), p.119-119, Article 119</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>The Author(s). 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c598t-253d217d1e8ed376bff2ae2f00965aac12744721448ecd6887d10af21168cb913</citedby><cites>FETCH-LOGICAL-c598t-253d217d1e8ed376bff2ae2f00965aac12744721448ecd6887d10af21168cb913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133766/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133766/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27906047$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:134950060$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Cardwell, Chris R</creatorcontrib><creatorcontrib>Pottegård, Anton</creatorcontrib><creatorcontrib>Vaes, Evelien</creatorcontrib><creatorcontrib>Garmo, Hans</creatorcontrib><creatorcontrib>Murray, Liam J</creatorcontrib><creatorcontrib>Brown, Chris</creatorcontrib><creatorcontrib>Vissers, Pauline A J</creatorcontrib><creatorcontrib>O'Rorke, Michael</creatorcontrib><creatorcontrib>Visvanathan, Kala</creatorcontrib><creatorcontrib>Cronin-Fenton, Deirdre</creatorcontrib><creatorcontrib>De Schutter, Harlinde</creatorcontrib><creatorcontrib>Lambe, Mats</creatorcontrib><creatorcontrib>Powe, Des G</creatorcontrib><creatorcontrib>van Herk-Sukel, Myrthe P P</creatorcontrib><creatorcontrib>Gavin, Anna</creatorcontrib><creatorcontrib>Friis, Søren</creatorcontrib><creatorcontrib>Sharp, Linda</creatorcontrib><creatorcontrib>Bennett, Kathleen</creatorcontrib><title>Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts</title><title>Breast cancer research : BCR</title><addtitle>Breast Cancer Res</addtitle><description>Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blockers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts.
Incident breast cancer patients were identified from eight cancer registries and compiled through the European Cancer Pharmacoepidemiology Network. Propranolol and non-selective beta-blocker use was ascertained for each patient. Breast cancer-specific and all-cause mortality were available for five and eight cohorts, respectively. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CIs) for cancer-specific and all-cause mortality by propranolol and non-selective beta-blocker use. HRs were pooled across cohorts using meta-analysis techniques. Dose-response analyses by number of prescriptions were also performed. Analyses were repeated investigating propranolol use before cancer diagnosis.
The combined study population included 55,252 and 133,251 breast cancer patients in the analysis of breast cancer-specific and all-cause mortality respectively. Overall, there was no association between propranolol use after diagnosis of breast cancer and breast cancer-specific or all-cause mortality (fully adjusted HR = 0.94, 95% CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively). There was little evidence of a dose-response relationship. There was also no association between propranolol use before breast cancer diagnosis and breast cancer-specific or all-cause mortality (fully adjusted HR = 1.03, 95% CI, 0.86, 1.22 and HR = 1.02, 95% CI, 0.94, 1.10, respectively). Similar null associations were observed for non-selective beta-blockers.
In this large pooled analysis of breast cancer patients, use of propranolol or non-selective beta-blockers was not associated with improved survival.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Care and treatment</subject><subject>Cohort Studies</subject><subject>Development and progression</subject><subject>Europe</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Proportional Hazards Models</subject><subject>Propranolol - therapeutic use</subject><subject>Propranolol hydrochloride</subject><subject>Treatment Outcome</subject><issn>1465-542X</issn><issn>1465-5411</issn><issn>1465-542X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>D8T</sourceid><recordid>eNptkk1vFSEUhonR2Fr9AW4MiRs3U4Hha1yYNE39SJroQhN3yGUOLZUZrjBzTf-9TOZae41hATnnOS-cw4vQc0pOKdXydaEtEbohVDZEadaIB-iYcikawdm3h_fOR-hJKTeEUKWFfoyOmOqIJFwdo--fc9pmO6aYIrZjj8ucd2FnI_Y5DXiTwZYJOzs6yG-wxduUIvSVtPG2hIKTxxdzlQA7HsLYpeuUp_IUPfI2Fni230_Q13cXX84_NJef3n88P7tsnOj01DDR9oyqnoKGvlVy4z2zwDwhnRTWOsoU54pRzjW4XmpdUWI9o1Rqt-loe4KaVbf8gu28MdscBptvTbLB7EM_6gmMIER2ovJvV75mBugdjFO28aDsMDOGa3OVdkbQtr5PVoFXe4Gcfs5QJjOE4iBGO0Kai6GaCyZEK0lFX_6D3qQ51xGuFG9VbeMvdWUjmDD6VO91i6g5q62L5dMWrdP_UHX1MASXRvChxg8K6Frgciolg7_rkRKz2MisNjLVRmaxkVmG8-L-cO4q_vim_Q1e9sMX</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Cardwell, Chris R</creator><creator>Pottegård, Anton</creator><creator>Vaes, Evelien</creator><creator>Garmo, Hans</creator><creator>Murray, Liam J</creator><creator>Brown, Chris</creator><creator>Vissers, Pauline A J</creator><creator>O'Rorke, Michael</creator><creator>Visvanathan, Kala</creator><creator>Cronin-Fenton, Deirdre</creator><creator>De Schutter, Harlinde</creator><creator>Lambe, Mats</creator><creator>Powe, Des G</creator><creator>van Herk-Sukel, Myrthe P P</creator><creator>Gavin, Anna</creator><creator>Friis, Søren</creator><creator>Sharp, Linda</creator><creator>Bennett, Kathleen</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20161201</creationdate><title>Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts</title><author>Cardwell, Chris R ; Pottegård, Anton ; Vaes, Evelien ; Garmo, Hans ; Murray, Liam J ; Brown, Chris ; Vissers, Pauline A J ; O'Rorke, Michael ; Visvanathan, Kala ; Cronin-Fenton, Deirdre ; De Schutter, Harlinde ; Lambe, Mats ; Powe, Des G ; van Herk-Sukel, Myrthe P P ; Gavin, Anna ; Friis, Søren ; Sharp, Linda ; Bennett, Kathleen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c598t-253d217d1e8ed376bff2ae2f00965aac12744721448ecd6887d10af21168cb913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Care and treatment</topic><topic>Cohort Studies</topic><topic>Development and progression</topic><topic>Europe</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Proportional Hazards Models</topic><topic>Propranolol - therapeutic use</topic><topic>Propranolol hydrochloride</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cardwell, Chris R</creatorcontrib><creatorcontrib>Pottegård, Anton</creatorcontrib><creatorcontrib>Vaes, Evelien</creatorcontrib><creatorcontrib>Garmo, Hans</creatorcontrib><creatorcontrib>Murray, Liam J</creatorcontrib><creatorcontrib>Brown, Chris</creatorcontrib><creatorcontrib>Vissers, Pauline A J</creatorcontrib><creatorcontrib>O'Rorke, Michael</creatorcontrib><creatorcontrib>Visvanathan, Kala</creatorcontrib><creatorcontrib>Cronin-Fenton, Deirdre</creatorcontrib><creatorcontrib>De Schutter, Harlinde</creatorcontrib><creatorcontrib>Lambe, Mats</creatorcontrib><creatorcontrib>Powe, Des G</creatorcontrib><creatorcontrib>van Herk-Sukel, Myrthe P P</creatorcontrib><creatorcontrib>Gavin, Anna</creatorcontrib><creatorcontrib>Friis, Søren</creatorcontrib><creatorcontrib>Sharp, Linda</creatorcontrib><creatorcontrib>Bennett, Kathleen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Breast cancer research : BCR</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cardwell, Chris R</au><au>Pottegård, Anton</au><au>Vaes, Evelien</au><au>Garmo, Hans</au><au>Murray, Liam J</au><au>Brown, Chris</au><au>Vissers, Pauline A J</au><au>O'Rorke, Michael</au><au>Visvanathan, Kala</au><au>Cronin-Fenton, Deirdre</au><au>De Schutter, Harlinde</au><au>Lambe, Mats</au><au>Powe, Des G</au><au>van Herk-Sukel, Myrthe P P</au><au>Gavin, Anna</au><au>Friis, Søren</au><au>Sharp, Linda</au><au>Bennett, Kathleen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts</atitle><jtitle>Breast cancer research : BCR</jtitle><addtitle>Breast Cancer Res</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>18</volume><issue>1</issue><spage>119</spage><epage>119</epage><pages>119-119</pages><artnum>119</artnum><issn>1465-542X</issn><issn>1465-5411</issn><eissn>1465-542X</eissn><abstract>Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blockers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts.
Incident breast cancer patients were identified from eight cancer registries and compiled through the European Cancer Pharmacoepidemiology Network. Propranolol and non-selective beta-blocker use was ascertained for each patient. Breast cancer-specific and all-cause mortality were available for five and eight cohorts, respectively. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CIs) for cancer-specific and all-cause mortality by propranolol and non-selective beta-blocker use. HRs were pooled across cohorts using meta-analysis techniques. Dose-response analyses by number of prescriptions were also performed. Analyses were repeated investigating propranolol use before cancer diagnosis.
The combined study population included 55,252 and 133,251 breast cancer patients in the analysis of breast cancer-specific and all-cause mortality respectively. Overall, there was no association between propranolol use after diagnosis of breast cancer and breast cancer-specific or all-cause mortality (fully adjusted HR = 0.94, 95% CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively). There was little evidence of a dose-response relationship. There was also no association between propranolol use before breast cancer diagnosis and breast cancer-specific or all-cause mortality (fully adjusted HR = 1.03, 95% CI, 0.86, 1.22 and HR = 1.02, 95% CI, 0.94, 1.10, respectively). Similar null associations were observed for non-selective beta-blockers.
In this large pooled analysis of breast cancer patients, use of propranolol or non-selective beta-blockers was not associated with improved survival.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27906047</pmid><doi>10.1186/s13058-016-0782-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-542X |
| ispartof | Breast cancer research : BCR, 2016-12, Vol.18 (1), p.119-119, Article 119 |
| issn | 1465-542X 1465-5411 1465-542X |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_500695 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SWEPUB Freely available online; PubMed Central Open Access; Springer Nature OA Free Journals |
| subjects | Adrenergic beta-Antagonists - therapeutic use Angiogenesis Inhibitors - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Care and treatment Cohort Studies Development and progression Europe Female Health aspects Humans Proportional Hazards Models Propranolol - therapeutic use Propranolol hydrochloride Treatment Outcome |
| title | Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T22%3A42%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Propranolol%20and%20survival%20from%20breast%20cancer:%20a%20pooled%20analysis%20of%20European%20breast%20cancer%20cohorts&rft.jtitle=Breast%20cancer%20research%20:%20BCR&rft.au=Cardwell,%20Chris%20R&rft.date=2016-12-01&rft.volume=18&rft.issue=1&rft.spage=119&rft.epage=119&rft.pages=119-119&rft.artnum=119&rft.issn=1465-542X&rft.eissn=1465-542X&rft_id=info:doi/10.1186/s13058-016-0782-5&rft_dat=%3Cgale_swepu%3EA472527900%3C/gale_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1845437116&rft_id=info:pmid/27906047&rft_galeid=A472527900&rfr_iscdi=true |